18.44
1.14 (6.59%)
| 前收盘价格 | 17.30 |
| 收盘价格 | 17.62 |
| 成交量 | 1,654,769 |
| 平均成交量 (3个月) | 983,079 |
| 市值 | 932,073,664 |
| 预期市盈率 (P/E Forward) | 19.72 |
| 价格/销量 (P/S) | 583.74 |
| 股市价格/股市净资产 (P/B) | 48.09 |
| 52周波幅 | |
| 利润日期 | 24 Mar 2026 |
| 稀释每股收益 (EPS TTM) | -3.69 |
| 总债务/股东权益 (D/E MRQ) | 3.98% |
| 流动比率 (MRQ) | 10.44 |
| 营业现金流 (OCF TTM) | -127.65 M |
| 杠杆自由现金流 (LFCF TTM) | -72.82 M |
| 资产报酬率 (ROA TTM) | -58.15% |
| 股东权益报酬率 (ROE TTM) | -150.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | KalVista Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.63 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.47% |
| 机构持股比例 | 112.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Vr Adviser, Llc | 31 Dec 2025 | 6,728,985 |
| Frazier Life Sciences Management, L.P. | 31 Dec 2025 | 5,039,867 |
| Point72 Asset Management, L.P. | 31 Dec 2025 | 2,283,766 |
| Woodline Partners Lp | 31 Dec 2025 | 1,921,092 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 1,890,000 |
| Kynam Capital Management, Lp | 31 Dec 2025 | 1,810,954 |
| Parkman Healthcare Partners Llc | 31 Dec 2025 | 1,768,508 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 37.00 (HC Wainwright & Co., 100.65%) | 购买 |
| 中 | 36.00 (95.23%) | |
| 低 | 35.00 (Needham, 89.81%) | 购买 |
| 平均值 | 36.00 (95.23%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 16.80 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jan 2026 | 37.00 (100.65%) | 购买 | 16.80 |
| Needham | 09 Jan 2026 | 35.00 (89.80%) | 购买 | 16.80 |
| 06 Jan 2026 | 32.00 (73.54%) | 购买 | 15.75 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合